# Cronos Group Inc.: financial statements, quarterly

CRON · Nasdaq · CIK 1656472 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cron.md) · [Financials](/companies/cron/financials.md) · [Filings](/companies/cron/filings.md) · [Insiders](/companies/cron/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cron/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.8](/filings/0001656472-24-000102.md) | [23.9 d](/filings/0001656472-26-000016.md) | [25.3](/filings/0001656472-25-000058.md) | [27.8](/filings/0001656472-25-000076.md) | [34.3](/filings/0001656472-25-000101.md) | [30.3 d](/filings/0001656472-26-000016.md) | [32.3](/filings/0001656472-26-000033.md) | [33.5](/filings/0001656472-26-000051.md) | [36.3](/filings/0001656472-25-000101.md) | [44.5 d](/filings/0001656472-26-000016.md) | [45.2](/filings/0001656472-26-000033.md) | [53.0](/filings/0001656472-26-000051.md) |
| Gross profit | $m | [4.0](/filings/0001656472-24-000102.md) | [1.9 d](/filings/0001656472-26-000016.md) | [4.5](/filings/0001656472-25-000058.md) | [6.3](/filings/0001656472-25-000076.md) | [3.6](/filings/0001656472-25-000101.md) | [10.8 d](/filings/0001656472-26-000016.md) | [13.7](/filings/0001656472-26-000033.md) | [14.5](/filings/0001656472-26-000051.md) | [18.3](/filings/0001656472-25-000101.md) | [16.2 d](/filings/0001656472-26-000016.md) | [19.2](/filings/0001656472-26-000033.md) | [28.5](/filings/0001656472-26-000051.md) |
| Research and development | $m | [1.2](/filings/0001656472-24-000102.md) | [1.5 d](/filings/0001656472-26-000016.md) | [1.0](/filings/0001656472-25-000058.md) | [1.0](/filings/0001656472-25-000076.md) | [1.2](/filings/0001656472-25-000101.md) | [1.0 d](/filings/0001656472-26-000016.md) | [0.8](/filings/0001656472-26-000033.md) | [0.9](/filings/0001656472-26-000051.md) | [1.3](/filings/0001656472-25-000101.md) | [1.4 d](/filings/0001656472-26-000016.md) | [1.4](/filings/0001656472-26-000033.md) | [1.2](/filings/0001656472-26-000051.md) |
| Operating income | $m | [(21.8)](/filings/0001656472-24-000102.md) | [(21.6) d](/filings/0001656472-26-000016.md) | [(15.9)](/filings/0001656472-25-000058.md) | [(15.6)](/filings/0001656472-25-000076.md) | [(33.7)](/filings/0001656472-25-000101.md) | [(11.4) d](/filings/0001656472-26-000016.md) | [(4.1)](/filings/0001656472-26-000033.md) | [(5.3)](/filings/0001656472-26-000051.md) | [(0.5)](/filings/0001656472-25-000101.md) | [(7.5) d](/filings/0001656472-26-000016.md) | [(1.8)](/filings/0001656472-26-000033.md) | [7.4](/filings/0001656472-26-000051.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.3)](/filings/0001656472-24-000102.md) | [(0.4) d](/filings/0001656472-26-000016.md) | [(0.6)](/filings/0001656472-25-000058.md) | [(2.2)](/filings/0001656472-25-000076.md) | [(2.7)](/filings/0001656472-25-000101.md) | [2.0 d](/filings/0001656472-26-000016.md) | [(0.5)](/filings/0001656472-26-000033.md) | [(0.5)](/filings/0001656472-26-000051.md) | [(1.3)](/filings/0001656472-25-000101.md) | [(11.9) d](/filings/0001656472-26-000016.md) | [2.4](/filings/0001656472-26-000033.md) | [0.1](/filings/0001656472-26-000051.md) |
| Net income | $m | [(1.6)](/filings/0001656472-24-000102.md) | [(44.8) d](/filings/0001656472-26-000016.md) | [(2.2)](/filings/0001656472-25-000058.md) | [(8.8)](/filings/0001656472-25-000076.md) | [8.3](/filings/0001656472-25-000101.md) | [43.7 d](/filings/0001656472-26-000016.md) | [6.1](/filings/0001656472-26-000033.md) | [(39.7)](/filings/0001656472-26-000051.md) | [26.0](/filings/0001656472-25-000101.md) | [(1.8) d](/filings/0001656472-26-000016.md) | [13.8](/filings/0001656472-26-000033.md) | [32.1](/filings/0001656472-26-000051.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001656472-24-000102.md) | not reported | [(0.01)](/filings/0001656472-25-000058.md) | [(0.02)](/filings/0001656472-25-000076.md) | [0.02](/filings/0001656472-25-000101.md) | not reported | [0.02](/filings/0001656472-26-000033.md) | [(0.10)](/filings/0001656472-26-000051.md) | [0.07](/filings/0001656472-25-000101.md) | not reported | [0.04](/filings/0001656472-26-000033.md) | [0.09](/filings/0001656472-26-000051.md) |
| Basic EPS | $ per share | [0.00](/filings/0001656472-24-000102.md) | not reported | [(0.01)](/filings/0001656472-25-000058.md) | [(0.02)](/filings/0001656472-25-000076.md) | [0.02](/filings/0001656472-25-000101.md) | not reported | [0.02](/filings/0001656472-26-000033.md) | [(0.10)](/filings/0001656472-26-000051.md) | [0.07](/filings/0001656472-25-000101.md) | not reported | [0.04](/filings/0001656472-26-000033.md) | [0.09](/filings/0001656472-26-000051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [572](/filings/0001656472-23-000147.md) | [669](/filings/0001656472-25-000014.md) | [855](/filings/0001656472-24-000063.md) | [848](/filings/0001656472-24-000089.md) | [862](/filings/0001656472-24-000102.md) | [859](/filings/0001656472-26-000016.md) | [798](/filings/0001656472-25-000058.md) | [794](/filings/0001656472-25-000076.md) | [784](/filings/0001656472-25-000101.md) | [792](/filings/0001656472-26-000051.md) | [822](/filings/0001656472-26-000033.md) | [467](/filings/0001656472-26-000051.md) |
| Current assets | $m | [918](/filings/0001656472-23-000147.md) | [933](/filings/0001656472-25-000014.md) | [942](/filings/0001656472-24-000063.md) | [935](/filings/0001656472-24-000089.md) | [959](/filings/0001656472-24-000102.md) | [936](/filings/0001656472-26-000016.md) | [919](/filings/0001656472-25-000058.md) | [927](/filings/0001656472-25-000076.md) | [922](/filings/0001656472-25-000101.md) | [944](/filings/0001656472-26-000051.md) | [928](/filings/0001656472-26-000033.md) | [912](/filings/0001656472-26-000051.md) |
| Total assets | $m | [1,150](/filings/0001656472-23-000147.md) | [1,140](/filings/0001656472-25-000014.md) | [1,109](/filings/0001656472-24-000063.md) | [1,091](/filings/0001656472-24-000089.md) | [1,184](/filings/0001656472-24-000102.md) | [1,166](/filings/0001656472-26-000016.md) | [1,154](/filings/0001656472-25-000058.md) | [1,175](/filings/0001656472-25-000076.md) | [1,178](/filings/0001656472-25-000101.md) | [1,197](/filings/0001656472-26-000051.md) | [1,172](/filings/0001656472-26-000033.md) | [1,180](/filings/0001656472-26-000051.md) |
| Current liabilities | $m | [30.6](/filings/0001656472-23-000147.md) | [41.4](/filings/0001656472-25-000014.md) | [33.4](/filings/0001656472-24-000063.md) | [33.1](/filings/0001656472-24-000089.md) | [39.6](/filings/0001656472-24-000102.md) | [49.7](/filings/0001656472-26-000016.md) | [33.0](/filings/0001656472-25-000058.md) | [37.6](/filings/0001656472-25-000076.md) | [41.1](/filings/0001656472-25-000101.md) | [48.2](/filings/0001656472-26-000051.md) | [42.4](/filings/0001656472-26-000033.md) | [56.4](/filings/0001656472-26-000051.md) |
| Total liabilities | $m | [33.3](/filings/0001656472-23-000147.md) | [44.1](/filings/0001656472-25-000014.md) | [35.8](/filings/0001656472-24-000063.md) | [35.3](/filings/0001656472-24-000089.md) | [52.8](/filings/0001656472-24-000102.md) | [55.3](/filings/0001656472-26-000016.md) | [39.1](/filings/0001656472-25-000058.md) | [45.0](/filings/0001656472-25-000076.md) | [46.4](/filings/0001656472-25-000101.md) | [54.2](/filings/0001656472-26-000051.md) | [48.3](/filings/0001656472-26-000033.md) | [62.4](/filings/0001656472-26-000051.md) |
| Shareholders' equity | $m | [1,120](/filings/0001656472-23-000147.md) | [1,100](/filings/0001656472-25-000014.md) | [1,076](/filings/0001656472-24-000063.md) | [1,059](/filings/0001656472-24-000089.md) | [1,082](/filings/0001656472-24-000102.md) | [1,064](/filings/0001656472-26-000016.md) | [1,066](/filings/0001656472-25-000058.md) | [1,082](/filings/0001656472-25-000076.md) | [1,083](/filings/0001656472-25-000101.md) | [1,094](/filings/0001656472-26-000051.md) | [1,074](/filings/0001656472-26-000033.md) | [1,069](/filings/0001656472-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.2) d](/filings/0001656472-24-000102.md) | [16.8 d](/filings/0001656472-26-000016.md) | [(2.2)](/filings/0001656472-25-000058.md) | [1.7 d](/filings/0001656472-25-000076.md) | [11.6 d](/filings/0001656472-25-000101.md) | [7.7 d](/filings/0001656472-26-000016.md) | [(2.1)](/filings/0001656472-26-000033.md) | [2.8 d](/filings/0001656472-26-000051.md) | [13.3 d](/filings/0001656472-25-000101.md) | [11.8 d](/filings/0001656472-26-000016.md) | [10.9](/filings/0001656472-26-000033.md) | [24.0 d](/filings/0001656472-26-000051.md) |
| Capital expenditure | $m | [(0.0) d](/filings/0001656472-24-000102.md) | [1.2 d](/filings/0001656472-26-000016.md) | [1.7](/filings/0001656472-25-000058.md) | [0.7 d](/filings/0001656472-25-000076.md) | [6.4 d](/filings/0001656472-25-000101.md) | [3.5 d](/filings/0001656472-26-000016.md) | [15.3](/filings/0001656472-26-000033.md) | [3.8 d](/filings/0001656472-26-000051.md) | [4.5 d](/filings/0001656472-25-000101.md) | [2.1 d](/filings/0001656472-26-000016.md) | [1.9](/filings/0001656472-26-000033.md) | [1.7 d](/filings/0001656472-26-000051.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001656472-25-000101.md) | [0.0 d](/filings/0001656472-26-000016.md) | [0.0](/filings/0001656472-26-000033.md) | [3.6 d](/filings/0001656472-26-000051.md) | [1.9 d](/filings/0001656472-25-000101.md) | [4.3 d](/filings/0001656472-26-000016.md) | [16.7](/filings/0001656472-26-000033.md) | [16.1 d](/filings/0001656472-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [378](/filings/0001656472-23-000147.md) | [381](/filings/0001656472-24-000063.md) | [381](/filings/0001656472-24-000089.md) | [381](/filings/0001656472-24-000102.md) | [381](/filings/0001656472-25-000058.md) | [382](/filings/0001656472-25-000076.md) | [386](/filings/0001656472-25-000101.md) | [387](/filings/0001656472-26-000033.md) | [385](/filings/0001656472-26-000051.md) | [385](/filings/0001656472-25-000101.md) | [382](/filings/0001656472-26-000033.md) | [375](/filings/0001656472-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 368,412,864 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001656472-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.